Have any questions? 706-721-6582 or cts@augusta.edu
- GOG-3092/ D7984C00002: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
Clinical Trial
GOG-3092/ D7984C00002: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
A Phase III study of Volrustomig compared to a placebo in women with high-risk cervical cancer who have previously been treated with chemoradiation therapy.
Eligibility Criteria
- Inclusion criteria Participants must be ? 15 years of age. Participants must have histologically confirmed cervical adenocarcinoma, cervical squamos carcinoma, or cervical adenosquamos carcinoma. A procured tumor sample to assess PD-L1 expression. Exclusion Criteria Diagnosis of small cell or mucinous adenocarcinoma of cervical cancer. Evidence of metastatic disease or other malignancy. Unresolved toxicities from previous treatment. Organ or stem cell transplant. Prior history of vesicovaginal, colovaginal, or rectovaginal fistula. Autoimmune disease(s).
RESEARCH. INNOVATION. DISCOVERY.